HHS Halts Shipments of Eli Lilly COVID-19 Antibody Cocktail

June 30, 2021

HHS has stopped shipping Eli Lilly’s COVID-19 antibody cocktail (bamlanivimab/etesevimab) because of the therapy’s lack of effectiveness against new variants of SARS-CoV-2.

The department made the decision after the cocktail failed to show efficacy in laboratory analyses against the variants first identified in Brazil and South Africa, which now account for more than 11 percent of COVID-19 infections in the U.S.

HHS previously halted U.S. deliveries of bamlanivimab in late March because the antibody wasn’t effective against certain coronavirus variants, and the FDA later revoked bamlanivimab’s Emergency Use Authorization as a COVID-19 monotherapy.

View today's stories